PV Bulletin
Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA)China

Technical Guidelines for Communication on Real-World Evidence Supporting the Extension of Pediatric Indications for Marketed Drugs (Draft for Comments)

The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Action needed

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-14
Policy change
The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population. It establishes a framework for communication between sponsors and the CDE to improve the efficiency of pediatric research.

Key changes

Provides technical considerations for using RWE data sources, study design, and data analysis to support pediatric label extensions. Emphasizes the need for early communication with CDE on RWE study plans.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsClinical DevelopmentPV Operations

PV impact

Affects how sponsors collect and present real-world safety and efficacy data for pediatric indication extensions in China.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 14, 2026

Full briefing

What changed

A draft guideline has been issued by the CDE outlining the framework for sponsors to use real-world evidence (RWE) when seeking to expand pediatric drug indications, highlighting the necessity for early discussions with the regulator on RWE study plans.

Why it matters

This change affects data collection and presentation for pediatric label extensions, potentially influencing the efficiency and speed of bringing pediatric drugs to market in China.

Practical implication

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

#labeling#Safety Signals#policy-change#consultation#firecrawl-policy-agent#Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA

Related updates for your role

publicFood and Drug Administration · United States · Updated Jul 13, 2026

Psychedelic Drugs: Considerations for Clinical Investigations

Urgency: High

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward
publicFDA · United States · Updated Jul 13, 2026

Formal Meetings Between the FDA and Sponsors of OTC Monograph Drugs

Urgency: High

Sponsors must adhere to defined meeting types (Type X, Y, Z) and submit meeting packages at least 3 months before planned submissions for OTC monograph drugs, ensuring FDA engagement occurs within set timelines.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Jul 13, 2026

Post-authorisation safety studies (PASS): Update on Assessment Timelines and Submission Requirements

Urgency: High

MAHs must ensure draft protocols are placed correctly in the CTD and that submission planning considers the clarified assessment timelines, with RMP updates contingent upon PRAC endorsement.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Q&A
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Jul 10, 2026

PRAC 6-9 July 2026: Agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata News Human Pharmacovigilance Download medicine d

Urgency: High

MAHs must execute safety communication plans, update Risk Management Plans (RMPs), and revise product information including the Summary of Product Characteristics (SmPC) and Package Leaflet.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, Labeling Lead
verifiedRegulatory action: Meeting Highlights
Read impact briefarrow_forward